2nd New Horizons in Immunotherapy for Head and Neck Cancer

2nd New Horizons in Immunotherapy for Head and Neck Cancer is organized by Pfiedler Enterprises, Inc and would be held during Dec 9 - 10, 2016 at La Valencia Hotel, La Jolla, California, United States of America. This CME conference has been approved with a maximum of 14 AMA PRA Category 1 Credits.

Target Audience
This conference is designed for leaders in head and neck cancer surgery who are interested in the advancements in the field of immunotherapy for the treatment of cancer patients.

Course Overview
This is the 2nd course designed to provide leaders in the field of head and neck cancer immune-oncologic to exchange ideas. Current research and advancements in treating head and neck cancer will be shared with those interested in this emerging field. Those attending will have an opportunity to gain an understanding of available immunotherapy agents and a rationale for ongoing and future clinical trials. This conference will be interactive and geared towards development of further strategies for development of clinical trials, implementing new therapies in the practice setting and looking to the future treatment of head and neck cancer.

Objectives
• Review recent developments in cancer immunotherapy for the treatment of head and neck cancer.
• Describe what is known about immune checkpoint blockade and design a strategy for testing these agents in head and neck cancer, alone and in combination with other immune modulators.
• Explain a rationale for the exploration of co-stimulatory agonists in the treatment of head and neck cancer.
• Discuss evolving vaccine strategies for the treatment of HPV-related and non-HPV related head and neck cancer.
• Discuss advances in neoantigen directed and adoptive cell therapy in head and neck cancer.
• Articulate the changes in the head and neck cancer tumor microenvironment and discuss methods to reverse immunosuppression.
• Describe current and emerging immunotherapy trials in head and neck cancer and explore future design strategies in combination with radiation, surgery and chemotherapy.